PE20050017A1 - PHARMACEUTICAL FORMULATION INCLUDING 5- [2-ETOXY-5 (4-METHYLPIPERAZIN-1-IL-SULFONIL) PHENYL] -1,6-DIHYDRO-1-METHYL-3-PROPYLPIRAZOLE [4,3-d] PYRIMIDIN-7- ONA CITRATE AND PROCESS FOR ITS MANUFACTURE - Google Patents
PHARMACEUTICAL FORMULATION INCLUDING 5- [2-ETOXY-5 (4-METHYLPIPERAZIN-1-IL-SULFONIL) PHENYL] -1,6-DIHYDRO-1-METHYL-3-PROPYLPIRAZOLE [4,3-d] PYRIMIDIN-7- ONA CITRATE AND PROCESS FOR ITS MANUFACTUREInfo
- Publication number
- PE20050017A1 PE20050017A1 PE2004000358A PE2004000358A PE20050017A1 PE 20050017 A1 PE20050017 A1 PE 20050017A1 PE 2004000358 A PE2004000358 A PE 2004000358A PE 2004000358 A PE2004000358 A PE 2004000358A PE 20050017 A1 PE20050017 A1 PE 20050017A1
- Authority
- PE
- Peru
- Prior art keywords
- sulfonil
- etoxy
- ona
- methylpiperazin
- pyrimidin
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UNA FORMULACION FARMACEUTICA MASTICABLE PARA ADMINISTRACION ORAL QUE COMPRENDE: (a) 5-[2-ETOXI-5(4-METILPIPERAZIN-1-IL SULFONIL)FENIL]-1,6-DIHIDRO-1-METIL-3-PROPIL PIRAZOLO [4,3-d] PIRIMIDIN-7-ONA CITRATO (SILDENAFIL) DE FORMULA I EN CONCENTRACIONES DE 1% A 40% SOBRE EL PESO TOTAL DE LA FORMULACION, Y (b) EXCIPIENTES FARMACEUTICAMENTE ACEPTABLES EN UN PORCENTAJE ENTRE 90% Y 95% DEL PESO TOTAL DE LA FORMULACION. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION DE DICHA FORMULACION QUE SE CARACTERIZA PORQUE LAS TABLETAS PRESENTAN MICROPOROS QUE PERMITEN UNA RAPIDA DESINTEGRACION POR EFECTO DE LA PENETRACION DE LA SALIVA Y SU ACCION SOBRE EL PRINCIPIO ACTIVOREFERS TO A CHEWABLE PHARMACEUTICAL FORMULATION FOR ORAL ADMINISTRATION, INCLUDING: (a) 5- [2-ETOXY-5 (4-METHYLPIPERAZIN-1-IL SULFONIL) PHENYL] -1,6-DIHYDRO-1-METHYL-3-PROPYL PIRAZOLO [4,3-d] PYRIMIDIN-7-ONA CITRATE (SILDENAFIL) OF FORMULA I IN CONCENTRATIONS OF 1% TO 40% ON THE TOTAL WEIGHT OF THE FORMULATION, AND (b) PHARMACEUTICALLY ACCEPTABLE EXCIPIENTS IN A PERCENTAGE BETWEEN 90% AND 95% OF THE TOTAL WEIGHT OF THE FORMULATION. IT ALSO REFERS TO A PROCEDURE FOR THE PREPARATION OF SUCH FORMULATION WHICH IS CHARACTERIZED BECAUSE THE TABLETS PRESENT MICROPORES THAT ALLOW A RAPID DISINTEGRATION BY THE EFFECT OF THE PENETRATION OF SALIVA AND ITS ACTION ON THE ACTIVE PRINCIPLE
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CO03029961A CO5330617A1 (en) | 2003-04-09 | 2003-04-09 | NEW ORAL SOLID DOSAGE FORM OF 5- [2-ETOXI-5 (4-METHYLPIPERAZIN-1-IL SULFONYL) PHENYL] -1,6-DIHYDRO-1-METHYL-3-PROPYLPIRAZOL [4,3-D] PIRIMIDIN- 7-ONA CITRATE AND PROCESS FOR MANUFACTURING |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20050017A1 true PE20050017A1 (en) | 2005-02-24 |
Family
ID=40435089
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2004000358A PE20050017A1 (en) | 2003-04-09 | 2004-04-07 | PHARMACEUTICAL FORMULATION INCLUDING 5- [2-ETOXY-5 (4-METHYLPIPERAZIN-1-IL-SULFONIL) PHENYL] -1,6-DIHYDRO-1-METHYL-3-PROPYLPIRAZOLE [4,3-d] PYRIMIDIN-7- ONA CITRATE AND PROCESS FOR ITS MANUFACTURE |
Country Status (4)
Country | Link |
---|---|
CO (1) | CO5330617A1 (en) |
EC (1) | ECSP045048A (en) |
GT (1) | GT200400059A (en) |
PE (1) | PE20050017A1 (en) |
-
2003
- 2003-04-09 CO CO03029961A patent/CO5330617A1/en not_active Application Discontinuation
-
2004
- 2004-03-31 GT GT200400059A patent/GT200400059A/en unknown
- 2004-04-06 EC ECSP045048 patent/ECSP045048A/en unknown
- 2004-04-07 PE PE2004000358A patent/PE20050017A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ECSP045048A (en) | 2004-05-28 |
GT200400059A (en) | 2005-02-01 |
CO5330617A1 (en) | 2003-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR048431A1 (en) | GALENIC FORMULATIONS OF ORGANIC COMPOUNDS | |
AR108594A2 (en) | PHARMACEUTICAL FORMULATIONS THAT KEEP FLAVOR WITH IMPROVED PHARMACEUTICAL CHARACTERISTICS | |
AR019935A1 (en) | SOLID PREPARATION OF QUICK DISINTEGRATION, USE OF A LITTLE CELLULOSE HYDROXIPROPIL REPLACED IN SUCH PREPARATION AND METHOD TO IMPROVE THE CAPACITY OF FAST DETACHMENT OF THE SAME | |
WO2006072940A3 (en) | Controlled long acting release pharmaceutical preparation for use in the oral cavity | |
BR122019027412B8 (en) | sustained release pharmaceutical composition in the form of microparticles, process for preparing said microparticles, and administration kit | |
MX2009003030A (en) | Galenic form for the trans-mucosal delivery of active ingredients. | |
CO6270217A2 (en) | GALENIC FORMULATIONS OF ALISQUIRENO AND VALSARTAN | |
ECSP034826A (en) | METHOD FOR MANUFACTURING A PHARMACEUTICAL COMPOSITION OF LOW DOSE | |
AR061166A1 (en) | PHARMACEUTICAL COMPOSITIONS FOR SUSTAINED RELEASE OF PHENYLPHERINE | |
AR062659A1 (en) | COMPOSITION OF LEVODOPA SUSTAINED RELEASE AND METHOD FOR USE | |
WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
ES2175663T3 (en) | SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING MILTEPHOSINE FOR ORAL ADMINISTRATION IN THE TREATMENT OF LESHMANIASIS. | |
AR061233A1 (en) | FORMULATION OF PROLONGED LIBERATION OF NALTREXONA | |
UY30847A1 (en) | USE OF DIANHYDROHEXITE MONONITRATE DERIVATIVES AS AGENTS FOR THE TREATMENT OF INTESTINAL DISORDERS | |
CO5580741A2 (en) | PHARMACEUTICAL COMPOSITION INCLUDING A 5HT1 RECEIVER AGONIST | |
AR065582A1 (en) | IMPROVEMENTS IN MEDICINAL COMPOSITIONS OR RELATED TO THE SAME | |
AR048970A1 (en) | SOLID PHARMACEUTICAL FORMULATION | |
MA32722B1 (en) | GALENIC FORMULATION COMPRISING ALISKIRENE AND ASSOCIATED PREPARATION METHOD BY FUSION-EXTRUSION GRANULATION | |
PE20050017A1 (en) | PHARMACEUTICAL FORMULATION INCLUDING 5- [2-ETOXY-5 (4-METHYLPIPERAZIN-1-IL-SULFONIL) PHENYL] -1,6-DIHYDRO-1-METHYL-3-PROPYLPIRAZOLE [4,3-d] PYRIMIDIN-7- ONA CITRATE AND PROCESS FOR ITS MANUFACTURE | |
ES2678122T3 (en) | Mucoadherent buccal tablets for the treatment of orofacial herpes | |
KR20200131913A (en) | Pharmaceutical compositions comprising flurbiprofen | |
BRPI0907203A2 (en) | Dosage form for oral transmucosal administration of triptans | |
PE20110923A1 (en) | PRE-COMPACTED RAPID DISINTEGRATION FORMULATIONS OF COMPOUNDS WITH LOW ORAL BIODAVAILABILITY | |
AR030551A1 (en) | USE OF NEFIRACETAM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE PROCESSING OF THE RESULTING PHARMACEUTICAL NEURODEGENERATION AND COMPOSITION | |
JP2009507850A5 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |